SequelSEC

QuidelOrtho Corp QDEL

In Vitro & In Vivo Diagnostic Substances · CIK 0001906324 · Fiscal year ends 0101

Revenue
$2.67B
Fiscal year ended 2026-06-28
Operating income
-$824.70M
Fiscal year ended 2026-06-28
Free cash flow
-$211.20M
Fiscal year ended 2026-06-28

QuidelOrtho Corp (QDEL) reported revenue of $2.67B and net income of -$1.05B for the fiscal year ended 2026-06-28. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from QuidelOrtho Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.

Income

QuidelOrtho Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-28
Revenue$2.67B
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$824.70M
Net income-$1.05B
Research & development$180.90M
Weighted-average diluted sharesUnavailable
Pretax income-$1.03B
Income tax expense$18.40M
Diluted EPSUnavailable
Selling, general & administrative$770.30M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

QuidelOrtho Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-28
Cash & equivalents$123.40M
Total assets$5.72B
Current assets$1.38B
Total liabilities$3.94B
Current liabilities$993.40M
Total equity incl. NCI$1.77B
Temporary (mezzanine) equityUnavailable
Inventory$618.90M
Accounts receivable$352.00M
GoodwillUnavailable
Long-term debt$2.54B
Accounts payable$236.50M

Cash flow

QuidelOrtho Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-28
Operating cash flow-$57.20M
Capital expenditures$154.00M
Investing cash flow-$244.80M
Financing cash flow$273.10M
Net change in cash-$28.30M
Stock-based compensation$44.20M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$454.20M

Derived

QuidelOrtho Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-28
Free cash flow-$211.20M
Gross marginUnavailable
Operating margin-30.8%
FCF margin-7.9%
SBC / revenue1.7%
Current ratio1.39x
Revenue YoY growth-2.5%
Net margin-39.2%
R&D / revenue6.8%
CapEx / revenue5.8%
Long-term debt / equity1.43x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open QDEL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.